Improving measles vaccine timing for better protection in children
Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings
This study is testing if giving the measles vaccine to children earlier can help them build better protection against measles.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 450 (estimated) |
| Ages | 23 Weeks to 28 Weeks |
| Sex | All |
| Sponsor | University of Oxford Academic / other |
| Locations | 1 site (Kampala) |
| Trial ID | NCT06667206 on ClinicalTrials.gov |
What this trial studies
This phase IIb clinical trial investigates the immune responses of children receiving two doses of the measles vaccine at different timepoints. A total of 450 children will be randomized into three groups, each receiving the measles-containing vaccine at varying intervals: group A at 6 and 12 months, group B at 9 and 18 months, and group C at 6 and 18 months. The study aims to determine if administering the first dose earlier at 6 months can enhance protection against measles in high incidence settings. Blood samples will be collected over two years to assess antibody levels and immune response.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy children aged 6 months who have received all previous vaccinations according to their country's immunization schedule.
Not a fit: Children with a recent family history of measles infection or those who have previously received any measles vaccination may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved measles protection for children in high-burden areas.
How similar studies have performed: Other studies have explored different vaccination schedules, but this specific approach of early dosing in high incidence settings is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
1. Trial Participants Children aged 6 months (23 - 28 weeks) at time of screening 2. Inclusion Criteria * Aged 6 months (23 - 28 weeks) at time of screening * Received all previous vaccines as per country Expanded Programme of Immunization (EPI) schedule, verified by child health card * Parents/caretakers willing to give informed consent for their and their children's participation and stay in the geographical area where the study would be conducted 3. Exclusion Criteria The participant may not enter the trial if any of the following apply: * Child not healthy enough to be vaccinated in the opinion of the investigator * Recent family history of measles infection (since birth) * Previous receipt of any measles vaccination * A family history of congenital or hereditary immunodeficiency other than HIV * Receipt of more than 1 week of immunosuppressant or immune modifying drugs e.g. high dose steroids. * Major congenital defects or serious chronic illness that in the opinion of the investigator are likely to modify immune responses or the ability to comply with the requirements of the study. * History of any neurological disorders or seizures * Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period * Other abnormalities or medical history that contraindicated measles vaccination
Where this trial is running
Kampala
- Makarere University - Johns Hopkins University Collaboration — Kampala, Uganda (Recruiting)
Study contacts
- Study coordinator: Oxford Vaccine Group
- Email: info@ovg.ox.ac.uk
- Phone: 01865 611400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.